ScopusElsevier Scopus
Status
Active
Coverage
2010–present
Source type
Journal
Open access
Yes
CiteScore
4.5
SJR · SCImago
1.028
Q2 SJR quartile
H-index
32
Best quartile
Q2 · 56th pctile
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Oncology | 188 / 428 | 56th | Q2 |
Compare journals
Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Lung Cancer: Targets and Therapy
Lung Cancer: Targets and Therapy is Scopus-indexed (Q2, CiteScore 4.5), WoS ESCI, DOAJ. Published by Dove Medical Press Ltd.
Checked against the index lists dated .
ISSN 1179-2728Verify ISSN ↗
Publisher: Dove Medical Press Ltd
Scopus · Q2WoS · ESCIOpen Access
4.5
CiteScore 2025
Q2
Best quartile
3
Indexed in
Cost to publish: Checking DOAJ for article charges…
Web of ScienceClarivate (SCIE/SSCI/AHCI/ESCI)
DOAJDirectory of Open Access Journals (live)
Listed in DOAJ
Open accessFully open access, peer reviewed
Not listed in: ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Quick answers
Is Lung Cancer: Targets and Therapy indexed in Scopus?
Yes — actively indexed in Scopus, coverage 2010–present, best quartile Q2, CiteScore 4.5.
What quartile is Lung Cancer: Targets and Therapy in Scopus?
Lung Cancer: Targets and Therapy is Q2 in Oncology (rank 188 of 428), by CiteScore 2025.
What is the impact factor of Lung Cancer: Targets and Therapy?
Lung Cancer: Targets and Therapy is indexed in the Emerging Sources Citation Index, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 4.5, which places it in quartile Q2 at the 56th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 1.028, quartile Q2, with an H-index of 32.
How much does it cost to publish in Lung Cancer: Targets and Therapy?
The publisher lists an article processing charge of about US$2,320 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Who publishes Lung Cancer: Targets and Therapy and what is its ISSN?
Lung Cancer: Targets and Therapy is published by Dove Medical Press Ltd. Its ISSN is 1179-2728.
Is Lung Cancer: Targets and Therapy in Web of Science?
Yes — indexed in the Emerging Sources Citation Index.
Is Lung Cancer: Targets and Therapy open access?
Yes — it is an open-access journal, listed in DOAJ.
How well cited is Lung Cancer: Targets and Therapy? — open metrics via OpenAlex
Lung Cancer: Targets and Therapy has an h-index of 35 and a 2-year mean of 2.53 citations per paper (OpenAlex). Its Scopus CiteScore is 4.5, quartile Q2. On 2-year citations it ranks #146 of 424 Scopus journals in Oncology.
35
h-index
2.53
2-yr mean citations
105
i10-index
218
works indexed
3,816
total citations
Publication fee · open access list price, US$
US$2,320
2-yr mean citations, among Scopus journals in the same subject
#146 of 424 Top 35% Oncology
Lung Cancer: Targets and Therapy published 17 papers in 2025; its busiest recent year was 2017 with 25. 2026* is the year so far.
Main topics
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
Who publishes in Lung Cancer: Targets and Therapy? — latest 78 articles, 2021–2026
In its latest 78 research articles (2021–2026), authors are most often from United States (44.2%), China (17.1%) and Japan (14.2%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Are there integrity warnings for Lung Cancer: Targets and Therapy? — indicators, not proof of misconduct
Scopus status: Active. No retracted papers are recorded. The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
- Scopus statusActive
- Retracted papers None recorded
- Problematic Paper Screener flags None flagged
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Official sources & links
Community experience: reader comments on this journal
Related journals
8 journals Journal Indexed in
Medical Devices: Evidence and Research Scopus Q2 WoS ESCI DOAJ Nanotechnology, Science and Applications Scopus Q3 WoS ESCI DOAJ Nature and Science of Sleep Scopus Q2 WoS SCIE DOAJ Neurobehavioral HIV Medicine Not in these indexes Neuropsychiatric Disease and Treatment Scopus Q2 WoS SCIE DOAJ NURSING-RESEARCH AND REVIEWS WoS ESCI DOAJ NUTRITION AND DIETARY SUPPLEMENTS WoS ESCI DOAJ OncoTargets and Therapy Scopus Q2 WoS SCIE
← Back to Journal Finder
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.